Huiyun Chang

Dr. Huiyun Chang


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2019 in PeerJ
Verified
Journal Article
Open access
PDF file
YLYao Lei
Yao Lei
FZFurong Zhao
Furong Zhao
JSJunjun Shao
Junjun Shao
YLYangfan Li
Yangfan Li
SLShifang Li
Shifang Li
YZYongguang Zhang
Yongguang Zhang
Several studies have shown that epitope vaccines exhibit substantial advantages over conventional vaccines. However, epitope vaccines are associated with limited immunity, which can be overcome by conjugating antigenic epitopes with built-in adjuvants (e.g., some carrier proteins or new biomaterials) with special properties, including immunologic specificity, good biosecurity and biocompatibility, and the ability to vastly improve the immune response of epitope vaccines. When designing epitope vaccines, the following types of built-in adjuvants are typically considered: (1) pattern recognition receptor ligands (i.e., toll-like receptors); (2) virus-like particle carrier platforms; (3) bacterial toxin proteins; and (4) novel potential delivery systems (e.g., self-assembled peptide nanoparticles, lipid core peptides, and polymeric or inorganic nanoparticles). This review primarily discusses the current and prospective applications of these built-in adjuvants (i.e., biological carriers) to provide some references for the future design of epitope-based vaccines.

1 November 2017 in International Immunopharmacology
Verified
Journal Article
Closed access
SLShi-Fang Li
Shi-Fang Li
FZFu-Rong Zhao
Fu-Rong Zhao
JSJun-Jun Shao
Jun-Jun Shao
YXYin-Li Xie
Yin-Li Xie
HCHuiyun Chang
Huiyun Chang
YZYong-Guang Zhang
Yong-Guang Zhang

1 January 2011 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
PDF file
JSJun-Jun Shao
Jun-Jun Shao
CWChung Kai Wong
Chung Kai Wong
TLTong Lin
Tong Lin
SLShuk Kwan Lee
Shuk Kwan Lee
GCGuo-Zheng Cong
Guo-Zheng Cong
JLJi-Xing Liu
Ji-Xing Liu
In order to develop a completely safe immunogen to replace the traditional inactivated vaccine, a tandem-repeat multiple-epitope recombinant vaccine against foot-and-mouth disease (FMD) virus (FMDV) type O was developed. It contained three copies each of residues 141 to 160 and 200 to 213 of VP1 of the O/China/99 strain of FMDV coupled with a swine immunoglobulin G heavy-chain constant region (scIgG). The data showed that the multiple-epitope recombinant vaccine elicited high titers of anti-FMDV specific antibodies in swine at 30 days postvaccination (dpv) and conferred complete protection against a challenge with 10350% swine infective doses of the O/China/99 strain. The anti-FMDV specific antibody titers were not significantly different between the multiple-epitope recombinant vaccine and the traditional vaccine (ttest,P> 0.05). The number of 50% pig protective doses was 6.47, which is higher than the number recommended by the World Organization for Animal Health. The multiple-epitope recombinant vaccine resulted in a duration of immunity of at least 6 months. We speculate that the multiple-epitope recombinant vaccine is a promising vaccine that may replace the traditional inactivated vaccine for the prevention and control of FMD in swine in the future.

10 February 2023 in Frontiers in Microbiology
Verified
Journal Article
Open access
SYSicheng Yang
Sicheng Yang
CMChun Miao
Chun Miao
WLWei Liu
Wei Liu
GZGuanglei Zhang
Guanglei Zhang
JSJunjun Shao
Junjun Shao
HCHuiyun Chang
Huiyun Chang
African swine fever virus (ASFV) is a highly infectious and lethal double-stranded DNA virus that is responsible for African swine fever (ASF). ASFV was first reported in Kenya in 1921. Subsequently, ASFV has spread to countries in Western Europe, Latin America, and Eastern Europe, as well as to China in 2018. ASFV epidemics have caused serious pig industry losses around the world. Since the 1960s, much effort has been devoted to the development of an effective ASF vaccine, including the production of inactivated vaccines, attenuated live vaccines, and subunit vaccines. Progress has been made, but unfortunately, no ASF vaccine has prevented epidemic spread of the virus in pig farms. The complex ASFV structure, comprising a variety of structural and non-structural proteins, has made the development of ASF vaccines difficult. Therefore, it is necessary to fully explore the structure and function of ASFV proteins in order to develop an effective ASF vaccine. In this review, we summarize what is known about the structure and function of ASFV proteins, including the most recently published findings.

18 October 2016 in Discover Nano
Verified
Journal Article
Open access
PDF file
ZLZezhong Liu
Zezhong Liu
FZFurong Zhao
Furong Zhao
SGShandian Gao
Shandian Gao
JSJunjun Shao
Junjun Shao
HCHuiyun Chang
Huiyun Chang
Chemiluminescence technique as a novel detection method has gained much attention in recent years owning to the merits of high sensitivity, wider linear ranges, and low background signal. Similarly, nanotechnology especially for gold nanoparticles has emerged as detection tools due to their unique physical and chemical properties. Recently, it has become increasingly popular to couple gold nanoparticles with chemiluminescence technique in biological agents’ detection. In this review, we describe the superiority of both chemiluminescence and gold nanoparticles and conclude the different applications of gold nanoparticle-initialed chemiluminescence in biomedical detection.

1 October 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
GMGong Mei-Jiao
Gong Mei-Jiao
LSLi Shi-Fang
Li Shi-Fang
CYChang Yan-Yan
Chang Yan-Yan
SJShao Jun-Jun
Shao Jun-Jun
SYSun Yue-Feng
Sun Yue-Feng
HCHuiyun Chang
Huiyun Chang
Foot-and-mouth disease virus (FMDV) is an important pathogen that affects livestock breeding and causes huge economic losses worldwide. Currently, the development of antiviral agents to combat FMDV infection at the early stages is being explored. As viral replication critically depends on the host for nucleoside supply, host enzymes involved in nucleotides biosynthesis may represent potential targets for the development of antiviral agents. In the present study, the effects of IMP dehydrogenase (AVN-944 and mycophenolate mofetil) and dihydroorotate dehydrogenase (teriflunomide) inhibitors were evaluated both in vitro and in vivo. The results revealed that these compounds were effective in suppressing FMDV (O/MY98/BY/2010 and A/GD/MM/2013) infection. With regard to the antiviral mechanism, time-of-addition experiments revealed that these compounds were effective when added at the early stages of viral lifecycle (0-8 h post infection). However, exogenous guanosine/uridine eliminated the antiviral activity of these compounds. Importantly, treatment AVN-944 and teriflunomide significantly improved the survival of mice that were subcutaneously treated with FMDV. Together, the results of the present study indicate the broad-spectrum activities of anti-FMDV agents targeting IMP dehydrogenase or dihydroorotate dehydrogenase, which could be useful in developing strategies to prevent FMD.